René Acosta-Isaac
A5004852788- Cardiac Arrhythmias and Treatments
- interferon and immune responses
- COVID-19 Clinical Research Studies
- Atrial Fibrillation Management and Outcomes
- Advanced biosensing and bioanalysis techniques
- COVID-19 and healthcare impacts
- Endoplasmic Reticulum Stress and Disease
- Liver Disease Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Cytomegalovirus and herpesvirus research
- Cardiac electrophysiology and arrhythmias
- Mitochondrial Function and Pathology
- Immunodeficiency and Autoimmune Disorders
- Pharmacological Effects and Toxicity Studies
- Metabolomics and Mass Spectrometry Studies
- Diabetes and associated disorders
- Long-Term Effects of COVID-19
- Antiplatelet Therapy and Cardiovascular Diseases
Hospital de Sant Pau
2021-2025
Abstract The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, COVID-19) had an estimated overall case fatality ratio of 1.38% (pre-vaccination), being 53% higher in males and increasing exponentially with age. Among 9578 individuals diagnosed COVID-19 the SCOURGE study, we found 133 cases (1.42%) detectable clonal mosaicism for chromosome alterations (mCA) 226 (5.08%) acquired loss Y (LOY). Individuals mosaic events (mCA and/or LOY) showed a 54% increase risk...
The frequency of mitochondrial DNA haplogroups (mtDNA-HG) in humans is known to be shaped by migration and repopulation. Mounting evidence indicates that mtDNA-HG are not phenotypically neutral, selection may contribute its distribution. Haplogroup H, the most abundant Europe, improved survival sepsis. Here we developed a random forest trained model for haplogroup calling using data procured from GWAS arrays. Our results reveal context SARS-CoV-2 pandemic, HV branch were found represent...
Anticoagulant therapy is a cornerstone treatment for coronavirus disease 2019 (COVID-19) due to the high rates of thromboembolic complications associated with this disease. We hypothesized that chronic antithrombotic could play protective role in patients hospitalized COVID-19. Retrospective, observational study all admitted our hospital ≥ 24 h from March 1 May 31, 2020 SARS-CoV-2. The objective was evaluate clinical outcomes and mortality COVID-19 receiving anticoagulation (AC) or...
Background and purpose Renal excretion of direct oral anticoagulants (DOACs) varies depending on the drug. Hypothetically, an increased glomerular filtration rate (GFR) may lead to suboptimal dosing a higher thromboembolic events incidence. However, real-world patient data do not support theoretical risk. The aim is analyse DOAC outcomes in patients with normal high (≥90 mL/min) GFR, focusing biological parameters thrombotic/haemorrhagic events. Methods Observational prospective...